Treatment of diabetic retinopathy: Recent advances and unresolved challenges

Figure 1 This drawing identifies many of the unresolved treatment questions pertaining to the evaluation and treatment of patients with diabetic retinopathy. The question marks highlight areas of controversy that are discussed in greater detail in the manuscript. VEGF: Vascular endothelial growth factor.

Figure 2 This figure shows sequential optical coherence tomography scans of a patient with diabetic macular edema. At baseline (A and B) the patient was given a series of 5 monthly injections of bevacizumab with no significant improvement in macular edema (C and D); one month after a single injection of the dexamethasone delivery system, the volume of edema had significantly improved (E and F).